Wave Life Sciences Ltd. (WVE) FY2025 10-K Annual Report
Wave Life Sciences Ltd. (WVE) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Wave Life Sciences Ltd. FY2025 10-K Analysis
Business Overview
- • Core business model: Clinical-stage biotech developing RNA medicines using proprietary PRISM® platform combining multi-modal RNA-targeting modalities and chemistry innovations
- • New emphasis on obesity program WVE-007 showing positive Phase 1 data with durable fat loss and muscle preservation, supporting once or twice yearly dosing
- • Strategic focus shift to RNA editing (AIMers) for rare genetic diseases like AATD (WVE-006) and PNPLA3 liver disease (WVE-008), advancing first-in-class oligonucleotide therapies
- • Clinical pipeline update: WVE-N531 for Duchenne muscular dystrophy granted FDA Rare Pediatric Disease and Orphan Drug Designations; FORWARD-53 trial showed functional muscle improvements
- • Noteworthy: Accelerated regulatory engagement initiated for WVE-006 AATD program with potential accelerated approval pathway feedback expected mid-2026
Management Discussion & Analysis
- • Revenue $42.7M in 2025 vs $108.3M in 2024, down $65.6M YoY due to Takeda agreement termination offset by GSK revenue increase
- • Operating loss widened to $215.4M in 2025 from $110.4M in 2024; operating margin -503.8% in 2025 vs -102.0% in 2024 (calculated as loss/ revenue)
- • Best segment R&D expenses: Other R&D including PNPLA3 and preclinical up $27.8M to $139.2M in 2025; worst segment HD program down $9.1M to $2.7M in 2025
- • Cash flow: Operating cash outflow $187.5M in 2025; financing inflows $488.2M driven by $377.8M public offering and $94.6M ATM sales; capex $0.7M in 2025
- • Outlook: Cash balance $602.1M at end 2025; expects funding sufficiency for 12+ months; notes risks in raising future capital tied to market conditions and business strategy
Risk Factors
- • Cybersecurity risk oversight by Audit Committee with quarterly updates on incidents and mitigation activities
- • Executive team including Data Security Officer and CFO with 50+ years combined cybersecurity experience managing risk
- • Incident response plan and reporting thresholds ensure timely Board-level awareness of significant cybersecurity breaches
Wave Life Sciences Ltd. FY2025 Key Financial MetricsXBRL
Revenue
$43M
▼ -60.5% YoY
Net Income
-$204M
▼ -110.7% YoY
Operating Margin
-504.1%
▼ -40215bp YoY
Net Margin
-478.3%
▼ -38876bp YoY
ROE
-39.4%
▲ +687bp YoY
Total Assets
$638M
▲ +81.3% YoY
EPS (Diluted)
$-1.21
▼ -72.9% YoY
Operating Cash Flow
-$187M
▼ -24.1% YoY
Source: XBRL data from Wave Life Sciences Ltd. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Wave Life Sciences Ltd.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.